Evidence map›Paper›PMID 35930793›Full record

ArticleThe Journal of urology2022

Satisfaction With Clinician-Led Germline Genetic Counseling in Patients With Prostate Cancer.

Sophia M Abusamra, Marissa A Solorzano, Mallory Luke, Jake Quarles, Michelle F Jacobs, Sanjay Das, Amy Kasputis, Linda A Okoth, Milan Patel, Mariana Seymore and 6 more

Open access · greenAbstract read
In one paragraph

Article in The Journal of urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Sophia M AbusamraDepartment of Urology, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0001-9588-5005
Marissa A SolorzanoDepartment of Urology, University of Michigan, Ann Arbor, Michigan.
Mallory LukeDepartment of Urology, University of Michigan, Ann Arbor, Michigan.
Jake QuarlesMichigan Institute of Urology, Troy, Michigan.
Michelle F JacobsDepartment of Internal Medicine, Division of Genetic Medicine, University of Michigan, Ann Arbor, Michigan.
Sanjay DasDepartment of Urology, University of Michigan, Ann Arbor, Michigan.
Amy KasputisDepartment of Urology, University of Michigan, Ann Arbor, Michigan.
Linda A OkothDepartment of Urology, University of Michigan, Ann Arbor, Michigan.
Milan PatelDepartment of Urology, University of Michigan, Ann Arbor, Michigan.
Mariana SeymoreDepartment of Urology, University of Michigan, Ann Arbor, Michigan.
Megan E V CaramDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
Rodney L DunnDepartment of Urology, Dow Division of Health Services Research, University of Michigan, Ann Arbor, Michigan.
Sofia D MerajverDepartment of Internal Medicine, Division of Genetic Medicine, University of Michigan, Ann Arbor, Michigan.
Elena M StoffelDepartment of Internal Medicine, Division of Genetic Medicine, University of Michigan, Ann Arbor, Michigan.
Zachery R ReichertDepartment of Internal Medicine, Hematology/Oncology Division, University of Michigan Medical School, Ann Arbor, Michigan.
Todd M MorganDepartment of Urology, Division of Urologic Oncology, University of Michigan, Ann Arbor, Michigan.
University of Michigan · USMichigan Institute of Urology · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI THEODORE S LAWRENCE · 1988 to 2026
$178.2M
Tissue/InformaticsP50CA186786 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Robert Timothy Dess · 2014 to 2026
$27.6M
Determining the clinical impact of gene expression testing in localized prostate cancerR01CA240991 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MORGAN, TODD M., SPRATT, DANIEL EIDELBERG · 2019 to 2024
$3.1M
NCI NIH HHS P30 CA046592NCI NIH HHS P50 CA186786NCI NIH HHS R01 CA240991
6 · The paper itself

Abstract

purposeIndications for germline testing in prostate cancer patients have expanded substantially over the past decade. With a near-universal shortage of genetic counselors and increasing demand, increased access to genetic counseling is crucial. We sought to prospectively implement and assess a clinician-led approach to genetic counseling and testing. MATERIALS AND

methodsPatients with metastatic or localized prostate cancer meeting National Comprehensive Cancer Network® criteria for consideration of genetic testing were offered pre-test genetic counseling by their urologist or medical oncologist as part of their routine clinical care and concurrently approached for enrollment in the Germline Genetics in Prostate Cancer Study. Consented patients filled out a post-counseling survey using validated instruments to assess the quality of counseling. For patients who elected to undergo genetic testing, an additional validated questionnaire was completed following disclosure of results. The primary outcome was the proportion of patients undergoing testing, with a target >60% of patients. The secondary outcome was overall satisfaction with counseling, with a target >85% of patients.

resultsA total of 275 patients enrolled, and 203 patients elected to undergo genetic testing. Post-counseling surveys were obtained from 265 patients, and post-genetic testing surveys were obtained from 132 patients. Patient satisfaction was high, with 98% of patients reporting being satisfied with the overall quality of pre-test counseling, and 74% of patients elected to undergo genetic testing.

conclusionsThese results support the effectiveness of clinician-led genetic counseling in prostate cancer. With clinician training, this approach can be utilized to expand access to appropriate germline genetic testing.

Indexed as

Genetic CounselingProstatic NeoplasmsGenetic TestingGerm CellsGerm-Line MutationHumansMalePatient SatisfactionPersonal Satisfactiongenetic counselinggenetic testinggerm-line mutationpatient satisfactionprostatic neoplasms

Identifiers

PMID35930793
PMCPMC10544847
OpenAlexW4289936607

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.